Sunitinib
규격
557795-19-4CAS 번호
111-194-2EC 번호
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamideIUPAC 명칭
C22H27FN4O2화학식
398.5 g/mol분자량
Sunitinib; 557795-19-4; SU-11248; SU11248; sunitinibum; Su-011248; NSC-750690; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide; SU011248; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; NSC-736511; V99T50803M; n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide; DTXSID1041134; CHEBI:38940; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; N-(2-(diethylamino)ethyl)-5-(((3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; RefChem:56080; DTXCID9021134; L01XE04; 111-194-2; 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide; Sutent; Sunitinib Base; 342641-94-5; N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; MFCD09260778; Sunitinib (INN); Sunitinib [INN]; C22H27FN4O2; CHEMBL535; SU 11248; NSC750690; Sunitinib (free base); Sunitinib [INN:BAN]; NCGC00164631-01; Sunitinib base?; s7781; UNII-V99T50803M; HSDB 7932; (Z)-Sunitinib; 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; Sutent (free base); Sunitinib (Standard); KS-5022; SUNITINIB [MI]; SUNITINIB [VANDF]; SCHEMBL8081; SUNITINIB [WHO-DD]; SUNITINIB [EMA EPAR]; BDBM4814; GTPL5713; orb1224671; orb1310675; orb3141251; Sutent, Sunitinib, SU11248; CHEBI:91430; EX-A553; WINHZLLDWRZWRT-ATVHPVEESA-N; HMS5085H20; HMS6018M17; HY-10255AR; K00588a; (E)-N-[2-(Diethylamono)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; Sunitinib base - Bio-X trade mark; EBC-12065; HY-10255A; NSC800937; T0374L; AKOS015908193; AKOS025312424; CCG-268638; CS-1670; DB01268; FD32120; NSC 736511; NSC 750690; NSC-800937; SDCCGSBI-0634415.P005; NCGC00164631-02; NCGC00164631-04; NCGC00164631-13; NCGC00164631-21; BD164426; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; SY013948; NS00004661; D08552; EN300-323230; H38037; AB01273976-01; AB01273976-02; AB01273976_04; Q417542; SR-00000000005; SR-00000000005-2; BRD-K42828737-001-03-3; BRD-K42828737-044-09-0; BRD-K42828737-044-10-8; BRD-K42828737-044-12-4; Q27163278; Z2568722545; 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; (Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3-indolinylidene)methyl]-2,4-dimethylpyrrole-3-carboxamide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-ethyl)-amide; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1 pound not2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2 pound not4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carbo동의어
Sunitinib 함유 제품
SUNITINIB VIATRIS 50 MG CAPSULAS DURAS EFGSUNITINIB VIATRIS 25 MG CAPSULAS DURAS EFGSUNITINIB VIATRIS 12,5 MG CAPSULAS DURAS EFGSUNITINIB TEVA 50 MG CAPSULAS DURAS EFGSUNITINIB TEVA 25 MG CAPSULAS DURAS EFGSUNITINIB TEVA 12,5 MG CAPSULAS DURAS EFGSUNITINIB ACCORD 50 mg CAPSULAS DURAS EFGSUNITINIB ACCORD 37,5 mg CAPSULAS DURAS EFGSUNITINIB ACCORD 25 mg CAPSULAS DURAS EFGSUNITINIB ACCORD 12,5 mg CAPSULAS DURAS EFGSUTENT 50 MG CAPSULAS DURASSUTENT 25 MG CAPSULAS DURAS
1/5 페이지
Sunitinib 판매 기업
VS
VIATRIS SANTEFranceSA
SANDOZFranceAH
Accord Healthcare S.L.U.SpainVL
Viatris LimitedSpainPE
PFIZER EUROPE MA EEIGBelgium1/2 페이지